Yao 2005.

Study name	Decreasing risk of coronary artery disease in schizophrenia by omega‐3 fatty acid supplementation (CAD)
Methods	Allocation: Randomised Endpoint classification: Efficacy study Intervention model: Parallel assignment Masking: Double‐blind (participant, caregiver, investigator, outcomes assessor) Primary Purpose: treatment
Participants	Adults aged 18 or over meeting: DSM‐IV criteria for schizophrenia (or schizoaffective disorder), major depression, or bipolar (depressed phase) disorder who are treated with antipsychotic, antidepressant or antimanic drugs and a lipid‐lowering drug (statin) for 2 months or longer
Interventions	Intervention: EPA (2 g in 4 x 500 mg soft gels daily) + antipsychotic drug (doctor's choice) treatment for baseline, 1 month, 2 months and 4 months duration Comparator: Placebo (soy bean oil, 2 g in 4 x 500 mg soft gels daily) + antipsychotic drug (doctor's choice) treatment for baseline, 1 month, 2 months and 4 months duration
Outcomes	Primary: To assess whether EPA supplementation can lead to improvement in further reducing CAD risk profile Secondary: To test whether EPA supplementation can simultaneously improve the psychiatric status of patients with schizophrenia
Starting date	September 2005
Contact information	Jeffrey Yao, University of Pittsburgh and VA Pittsburgh Healthcare System
Notes	No working contact details